pre-IPO PHARMA

COMPANY OVERVIEW

Clover Biopharmaceuticals is a global, clinical-stage, research-based biotechnology company focused on discovering, developing and commercializing transformative biologic therapies, with a focus on oncology and autoimmune diseases. Clover is utilizing its proprietary Trimer-Tag technology platform to develop novel biologics targeting trimerization-dependent pathways. Additionally, Clover is leveraging its in-house cGMP biomanufacturing capabilities to develop select biosimilars.


LOCATION

  • Chengdu, , China

  • THERAPEUTIC AREAS

  • Autoimmune Disease
  • Infectious Disease
  • Oncology
  • Vaccines

  • WEBSITE

    https://www.cloverbiopharma.com


    CAREER WEBSITE

    https://www.cloverbiopharma.com/index.php?m=content&c=index&a=lists&catid=19


    SOCIAL MEDIA


    INVESTORS



    PRESS RELEASES


    Dec 9, 2021

    Ascentage Pharma and Clover Biopharmaceuticals Announce Clinical Collaboration to Evaluate IAP Antagonist, APG-1387, plus the Recombinant Human TRAIL-Trimer Fusion Protein, SCB-313, for the Treatment of Peritoneal Carcinomatosis


    Sep 22, 2021

    COVID-19 Vaccine Developed by Clover Biopharmaceuticals Using Dynavax's CpG 1018 Adjuvant Meets Primary and Secondary Efficacy Endpoints in Global Phase 2/3 Trial


    Sep 9, 2021

    Clover Biopharmaceuticals Receives Pharmaceutical Manufacturing Permit from Zhejiang Medical Products Administration to Produce COVID-19 Vaccine


    Jul 6, 2021

    Clover Biopharmaceuticals Completes Enrollment of Adult and Elderly Population in SPECTRA Global Phase 2/3 Clinical Trial for its COVID-19 Vaccine Candidate


    Mar 24, 2021

    Clover Biopharmaceuticals and Dynavax Announce First Participants Dosed in SPECTRA, a Global Phase 2/3 Clinical Trial for Adjuvanted S-Trimer COVID-19 Vaccine Candidate


    For More Press Releases


    Google Analytics Alternative